Mucopolysaccharidosis Stocks List

Recent Signals

Date Stock Signal Type
2021-05-14 BMRN Lower Bollinger Band Walk Weakness
2021-05-14 BMRN Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-05-14 RARE Crossed Above 20 DMA Bullish
2021-05-14 RARE Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-05-14 RARE Calm After Storm Range Contraction
2021-05-14 RGNX Crossed Above 50 DMA Bullish
2021-05-14 RGNX 200 DMA Resistance Bearish

Recent News for Mucopolysaccharidosis Stocks

Date Stock Title
May 14 RGNX Dr Reddy's Rolls Out Sputnik V COVID-19 Vaccine In India At $13.58/Dose
May 14 RGNX Regenxbio's Hunter Syndrome Gene Therapy Shows Efficacy Signals, Cognitive Development Up To Two Years
May 14 RARE Ultragenyx's Gene Therapies For Genetic Metabolic Disorders Show Longer-Term Durable Responses
May 14 RARE Ultragenyx reports positive long-term data from Phase 1/2 gene therapy studies in GSDIa and OTC deficiency
May 14 RARE Ultragenyx Announces Positive Multi-Year Durability Data from Ongoing Phase 1/2 Gene Therapy Studies and Data on HeLa 3.0 Manufacturing Platform at American Society of Gene & Cell Therapy 2021 Annual Meeting
May 14 RGNX Regenxbio reports positive interim data from mid-stage RGX-121 study in Hunter Syndrome
May 14 RGNX REGENXBIO Presents Additional Positive Interim Data from Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at American Society of Gene and Cell Therapy's 24th Annual Meeting
May 14 RGNX Regenxbio: An Overlooked Gene Therapy Innovator
May 12 BMRN BioMarin Announces 6 Presentations at American Society of Gene and Cell Therapy (ASGCT) Virtual 2021 Annual Meeting
May 12 RGNX Regenxbio: Better Investment Case Than Adverum
May 10 SGTX Sigilon Therapeutics EPS misses by $0.01, misses on revenue
May 10 SGTX Sigilon Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights
May 10 RARE Ultragenyx to Present at Bank of America Securities Healthcare Conference
May 10 RARE New Strong Sell Stocks for May 10th
May 10 RARE Kyowa Kirin wins European nod for self-administered CRYSVITA
Related Industries: Biotechnology

Mucopolysaccharidoses are a group of metabolic disorders caused by the absence or malfunctioning of lysosomal enzymes needed to break down molecules called glycosaminoglycans (GAGs). These long chains of sugar carbohydrates occur within the cells that help build bone, cartilage, tendons, corneas, skin and connective tissue. GAGs (formerly called mucopolysaccharides) are also found in the fluids that lubricate joints.
Individuals with mucopolysaccharidosis either do not produce enough of one of the eleven enzymes required to break down these sugar chains into simpler molecules, or they produce enzymes that do not work properly. Over time, these GAGs collect in the cells, blood and connective tissues. The result is permanent, progressive cellular damage which affects appearance, physical abilities, organ and system functioning.
The mucopolysaccharidoses are part of the lysosomal storage disease family, a group of more than 40 genetic disorders that result when the lysosome organelle in animal cells malfunctions. The lysosome can be thought of as the cell's recycling center because it processes unwanted material into other substances that the cell can utilize. Lysosomes break down this unwanted matter via enzymes, highly specialized proteins essential for survival. Lysosomal disorders like mucopolysaccharidosis are triggered when a particular enzyme exists in too small an amount or is missing altogether.

More about Mucopolysaccharidosis
Browse All Tags